Featured Post

Do Candidates and Clients All Lie?

  When I first joined the recruiting business ten years ago, there was a veteran recruiter in the office who shared with me his “secret” for recruiting success. “Scott, when it comes to candidates and clients, remember this: T. A. L.” I asked him what T. A. L. stood for and he said, “They...

Read More

Intuitive Surgical third quarter earnings up 10% from 2013

Posted by Joe Baker | Posted in BioTech News, General, Industry News, Medical Device News, Press Release | Posted on 22-10-2014




Intuitive Surgical, Inc. (Nasdaq:ISRG), the industry leader in robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2014.

Q3 Highlights

  • Worldwide da Vinci procedures grew nearly 10% over the third quarter of 2013.
  • The Company placed 111 da Vinci Surgical Systems, compared to 101 in the third quarter of 2013 and 96 in the second quarter of 2014.
  • The Company increased da Vinci Xi System sales from 50 during the second quarter of 2014, the quarter of launch, to 59 in the third quarter of 2014.
  • The Company’s Firefly fluorescence imaging product was cleared by the FDA for use with da Vinci Xi.
  • The Company’s wristed Single-Site needle driver was cleared by the FDA for use on benign hysterectomy, cholecystectomy, and salpingo-oophorectomy procedures.

Q3 Financial Summary

Revenue in the third quarter of 2014 was $550 million, an increase of approximately 10% compared with $499 million in the third quarter of 2013.

Third quarter 2014 GAAP instrument and accessory revenue increased by approximately 14% to $273 million compared with$239 million for the third quarter of 2013. The increase in revenue was driven by approximately 10% higher da Vinci procedure volume and timing of customer orders. Higher procedure volume was driven by growth in U.S. general surgery procedures and worldwide urologic procedures.

Systems revenue increased to $169 million in the third quarter of 2014, compared with $159 million for the third quarter of 2013. Systems revenue decreased to $154 million in the third quarter of 2014, compared with $159 million for the third quarter of 2013. Intuitive Surgical shipped 111 da Vinci Surgical Systems during the three months ending September 30, 2014, compared with 101 in the same period last year.

Intuitive Surgical ended the third quarter of 2014 with $2.3 billion in cash, cash equivalents, and investments, an increase of$219 million during the quarter, primarily driven by cash generated from operations.

Commenting on the announcement, Dr. Gary Guthart, President and CEO of Intuitive Surgical, said, “We are pleased with our third quarter procedure and da Vinci system placement growth, the positive surgeon response to our da Vinci Xi System, and our progress in expanding our international business.”

Make your LinkedIn summary work for you

Posted by Joe Baker | Posted in Career Advice, Career Development, Interviewing Tips, Linkedin Tips | Posted on 22-10-2014


You already know the importance of a great picture on your LinkedIn profile (the post is here if you haven’t yet read it). But, your profile needs to have as much substance as it has style. With the right tweaks and edits, your professional profile will help—instead of hinder—your chances at getting to the next step in your career.


Your profile summary should clearly and concisely describe where you are in your career, your key skills and experience, as well as give the reader a sense of your career ambitions. Your summary is not the place for personal information and PLEASE double-check for spelling and grammar mistakes. Many readers will miss a typo here or there, but others of us hone in on them like a cat on a laser light!

The summary is your opportunity to say things that aren’t traditional, or won’t fit, on your resume. So, be sure to write something that reflects a little of your winning personality—within the bounds of professionalism.

Not sure how your LinkedIn profile measures up? Let us know. If you’re creative writing skills aren’t up to task, or you don’t have the time to make an all-star LinkedIn profile, Medical Sales Coaching provides a profile review (with recommendations) at no charge.


inFlow receives FDA approval for women with IDC

Posted by Joe Baker | Posted in BioTech News, Diagnostic News, General, Industry News, Medical Device News, Press Release | Posted on 20-10-2014



The inFlow Intraurethral Valve-Pump, manufactured by Vesiflo, Inc. in Redmond, Washington has received approval from the U.S. Food and Drug Administration. The inFlow is a replaceable urinary prosthesis for women unable to contract the muscles necessary to push urine out of the bladder (impaired detrusor contractility or IDC).inFlow

IDC is a condition which can result from significant neurologic disease or injury such as stroke, multiple sclerosis, spinal cord injury, spina bifida or diabetic neuropathy. IDC is typically managed with various types of catheters, including clean intermittent catheterization (CIC).

“The inFlow device allows women with IDC to urinate, without the need to catheterize daily or be attached to a urine drainage bag,” said William Maisel, M.D., M.P.H., deputy director for science and chief scientist in the FDA’s Center for Devices and Radiological Health. “This may allow for increased mobility and the ability to be more self-sufficient.”